Detection of Cytochrome P450-2A6, -3A5 and -4B1 with Real-Time Polymerase Chain Reaction in Prostate Tissue

Sevil Zencir\textsuperscript{a,e}, Davut Alptekin\textsuperscript{b}, Medih Celiktas\textsuperscript{c}, Pakize Canturk\textsuperscript{d}, Deniz Colak\textsuperscript{c}, Vildan Caner\textsuperscript{a}, Umit H. Luleyap\textsuperscript{b}, and Zeki Topcu\textsuperscript{d,*}
\textsuperscript{a} Department of Medical Biology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
\textsuperscript{b} Department of Medical Biology, School of Medicine, Cukurova University, Adana, Turkey
\textsuperscript{c} Department of Radiodiagnostics, School of Medicine, Cukurova University, Adana, Turkey
\textsuperscript{d} Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, Izmir, Turkey. Fax: (90) 232388 5258. E-mail: zeki.topcu@ege.edu.tr
\textsuperscript{e} Present address: Department of Biochemistry, Faculty of Science, Ege University, Izmir, 35100, Turkey
\textsuperscript{*} Author for correspondence and reprint requests

Z. Naturforsch. 63c, 780–784 (2008); received February 25/April 10, 2008

Cytochrome P450 (CYP) is a heme-containing enzyme superfamily metabolizing a wide variety of xenobiotics, including drugs and carcinogens. The majority of CYP genes are expressed in the liver, however, some CYP isoforms are also reported for a number of extra hepatic tissues. We analyzed Cytochrome P450-2A6, -3A5 and -4B1 mRNAs using real-time reverse-transcriptase polymerase chain reaction (RT-PCR) in a total of 21 homogenized prostate tissues with or without malignancy. We detected a consistent expression of CYP2A6 and CYP3A5 in all, and of CYP4B1 in some (11/21) of the samples at mRNA level. Neither the histopathological status nor the smoking habit of the individuals affected CYP4B1 expression. Our results reflect possible roles for these particular CYPs in therapy and protection of prostate tissue.

Keywords: Prostate, Cytochrome P450 Expression

Introduction

Human Cytochrome P450 (CYP) comprises a multigene family of microsomal enzymes that carry out the oxidative metabolism of numerous endogenous and exogenous compounds (Gonzales, 1992). About 20 individual CYP forms, capable of metabolizing xenobiotics, have been identified in man. Although most of the CYP gene family is expressed most abundantly in the liver, some CYP isoforms were also reported in a number of extra hepatic tissues (Vondracek et al., 2001; Ding and Kaminsky, 2003; Sarikaya et al., 2007). Over the past years there has been an increased number of researches on the relationship between CYP expression and cancer because altered CYP isoforms could either decrease or increase the metabolism of certain anticancer drugs leading to cytotoxicity in some patients (Purnapatre et al., 2008). The human prostate is one of the most common sites of pathology among the male population. It is the fifth most common cause of male cancer mortality in the world and the second most common cancer in men (Al-Buheissi et al., 2006). The therapeutical strategy of prostate cancer (PC) frequently employs pharmaceuticals that suppress androgens (Finnstrom et al., 2001). Because androgens may serve as the substrates for CYPs, the expression of CYP isoforms in prostate is important. The presence or absence of certain CYP isoforms can determine the rate of activation of potential carcinogens and the outcome of therapy involving P450 substrates (Ragavan et al., 2006). Moreover, some CYP isoforms are polymorphic, which might contribute to differences in interindividual susceptibility to environmental carcinogens (Topcu et al., 2002; Agundez, 2004). The aim of this study was to analyze the expression of the individual forms of CYP genes at the mRNA level in human prostate tissue. Individual forms of CYP mRNAs were detected by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) using specific primers for the CYP2A6, -3A5 and -4B1 genes.

Materials and Methods

Tissue samples RNA extraction and cDNA synthesis

Prostate needle biopsies (10 to 50 mg) were obtained from a total of 21 patients who visited Cu-
kurova University Hospital, Adana, Turkey. A written informed consent was obtained from each patient and the study was approved by the Ethics Committee of the University. Characteristics of the subjects, covered in this study are summarized in Table II.

The samples were frozen immediately in liquid nitrogen and homogenized in a microtube using a cell lyser for RNA isolation (Retsch, Haan, Germany). Total RNA was isolated using the “High Pure RNA Tissue Kit”, and complementary DNA was synthesized using the RNA-PCR kit according to the manufacturer’s specifications (Roche, Penzberg, Germany). Reverse transcription was carried out at 65 °C for 10 min, followed by incubation at 55 °C for 30 min and 85 °C for 5 min. The products were exclusively evaluated for GAPDH using conventional PCR to check the fidelity of cDNA synthesis. The primers for detecting CYP3A5, -4B1 and GAPDH were purchased as “Human Cytochrome P 450 Competitive RT-PCR Kit” (Takara, Tokyo, Japan). The CYP2A6 primer set was designed using GenBank database (accession numbers: NM 00762 and NG 000008); 5′-CCCTCAT-GAAGATCAGTGAGC-3′ forward and 5′-CGCTCCCCGTTGCTGAATA-3′ reverse primer, giving a band of 200 bp upon PCR amplification. Polymerase chain reactions were carried out in a solution of 20 μL containing 0.1 μg of cDNA, 1 unit Taq DNA polymerase and 20 pmol of each primer. The PCR conditions consisted of an initial denaturation at 94 °C for 2 min, followed by 30 cycles of denaturation at 94 °C for 30 s, annealing at 56 °C for 30 s and polymerization at 72 °C for 1 min (Sarikaya et al., 2007). Reaction products were analyzed on 2% agarose gels in Tris-Borate-EDTA (TBE) buffer (5 V/cm), and gels were photographed under UV light after staining with ethidium bromide (0.5 μg/mL). To control the reproducibility, all amplifications were repeated at least once. A visible band in agarose gel was regarded as a sign of the presence of corresponding mRNA.

Real-time PCR analysis

RT-PCRs were carried out using a LightCycler instrument (Roche Diagnostics, Mannheim, Germany) and a “LightCycler FastStart DNA Master SYBR Green I Kit” (Roche Applied Science, Indianapolis, IN, USA). For each reaction, the optimized reaction mixture contained 2 μL of LightCycler FastStart Master SYBR Green I, 12.4 μL of PCR-grade H2O, 1.6 μL of 25 mmol/L MgCl2, 2 μL of 10 mmol/L primer set, and 2 μL of template cDNA. Amplification melting curve analysis was performed thereafter using the program run for one cycle at 95 °C for 1 s hold followed by a slow decrease in the temperature (−0.1 °C/s) and set at continuous acquisition mode. Negative controls without cDNA template were included with every PCR run and were always negative (not shown). All RT-PCR protocols used in this study are presented in Table I.

Results and Discussion

The aim of this study was to detect the mRNAs for CYP2A6, CYP3A5 and CYP4B1 in the target tissue. The expression of CYPs can be determined by various methods including immunoblotting, immunohistochemistry and RT-PCR (Senft and Levine, 2005). Given that the interpretation of immunoblotting and immunohistochemistry methods is complicated because of the possible non-specific binding of antibodies, RT-PCR is generally considered as a sensitive and powerful method for detection and amplification of low levels of mRNA expression (O’Connell, 2002).

Serum measurement of prostate-specific antigen (PSA), an androgen-regulated serine protease, has been widely used as tumour marker for the early detection of PC and monitoring cancer progression (Gsur et al., 2004). The patients who participated in this study were compared on the basis of PSA as well as age parameters using Mann-Whitney U test (SPSS version 10.0). The ages shown as means ± SD of subjects with malign tumour (5/21) and of subjects without malignancy (16/21)

### Table I. The PCR programs for real-time PCR with LightCycler FastStart DNA Master SYBR Green I for the CYP isoforms tested in this study.

<table>
<thead>
<tr>
<th>Program</th>
<th>Gen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CYP2A6</td>
</tr>
<tr>
<td>Pre-incubation</td>
<td>95 °C/30 s</td>
</tr>
<tr>
<td>Amplification</td>
<td>95 °C/0 s</td>
</tr>
<tr>
<td></td>
<td>58 °C/5 s</td>
</tr>
<tr>
<td>amplification</td>
<td>72 °C/17 s</td>
</tr>
<tr>
<td>Melting curve</td>
<td>95 °C/20 s</td>
</tr>
<tr>
<td></td>
<td>55 °C/20 s</td>
</tr>
<tr>
<td></td>
<td>95 °C/0 s</td>
</tr>
<tr>
<td>(slope = 0.1 °C/s)</td>
<td>(slope = 0.1 °C/s)</td>
</tr>
<tr>
<td>Cooling</td>
<td>40 °C/30 s</td>
</tr>
</tbody>
</table>
were (65.1 ± 8.2) years (range, 52–77) and (59.6 ± 8.7) years (range, 50–70), respectively (Table II). There was no statistically significant difference either in the mean age ($p = 0.303$) or PSA values ($p = 0.231$) between the subjects with malign tumour and the subjects without malignancy (Table II). RT-PCR gene expression analyses were carried out without prior knowledge of the histopathological findings.

To check the reliability of our method, we first used a positive control primer set for GAPDH in the conventional PCR after the synthesis of cDNAs from isolated total RNA from the tissue samples. The results for a representative number of samples (14 out of 21) are given in Fig. 1. Our results showed the bands for amplified GAPDH at the expected molecular weight (546 bp) (Fig. 1, lanes 1 to 14). No amplification was observed in the negative control reaction, which was set by omitting template cDNA (data not shown).

The gene expression of 3 different CYP genes, CYP2A6, CYP3A5 and CYP4B1, were detected by using RT-PCR combined with melting curve analysis in a total of 21 human prostatic tumour and non-tumour samples. A representative melting curve analysis of CYP3A5 gene expression is given in Fig. 2. The melting temperatures of CYP2A6, CYP3A5 and CYP4B1 were determined to be 78.0 °C, 84.2 °C and 84.0 °C, respectively (Fig. 2 and data not shown). CYP2A6 and CYP3A5 mRNAs were detected in all the 21 prostate samples, while CYP4B1 expression was seen in 11 out of the 21 samples (Table III). Therefore, our statistical evaluation using Fischer’s $\chi^2$ test covered only CYP4B1 expression. As seen in Ta-
Fig. 2. Melting curve analysis of amplified samples with cDNA for the detection of CYP3A5 gene expression. Template cDNA was replaced by PCR-grade water as negative control. The samples showed a characteristic sharp decrease in fluorescence at about 84°C by melting curve analysis obtained by plotting the negative derivative of fluorescence over temperature (−d/dT) versus temperature (T).

Table III, 60% of the PC samples were found to have CYP4B1 mRNAs while 50% of the control subjects were positive for CYP4B1 (Table III). When the results were analyzed on the basis of the smoking habit of the subjects, 67% of the smokers were found to be positive for the detection of CYP4B1 mRNA while only 33% of non-smokers were CYP4B1 positive (Table III). Statistical evaluation of the results showed that neither histopathological status nor the smoking habit of the subjects differed from each other significantly in CYP4B1 expression (p = 1.00 and p = 0.198, respectively). Because only one of the total 21 subjects had alcohol consumption, we did not carry out a statistical analysis on the basis of this variable.

The expression of CYP3A5 was reported in prostate and other extrahepatic tissues by a number of researchers using the RT-PCR methodology (Murray et al., 1995; Yamakoshi et al., 1999; Finnstrom et al., 2001; Nishimura et al., 2003). A more recent study reported the CYP3A5 expression in normal prostate cells but not in prostate cancer cells (Leskelä et al., 2007). The presence of CYP3A5 was attributed to the excretion of testosterone and progesterone from prostate by altering them to polar metabolites in these studies. The latter group also reported the presence of CYP4B1, but not CYP2A6, in prostate tissue (Nishimura et al., 2003). Another study reported CYP4B1 mRNAs in the majority of 28 prostate tissue samples (Finnstrom et al., 2001). This CYP isoform participates in the metabolism of certain xenobiotics that are prototoxic, including valproic acid, 3-methylindole, 4-ipomeanol, 3-methoxy-4-aminooazobenzene, and numerous aromatic amines (Finnstrom et al., 2001). Therefore, the presence or absence of CYP4B1 is important as we found that not all prostate samples resulted in CYP4B1 expression (Table III). CYP2A6, on the other hand, represents a relatively minor component (~4%) of the human CYPs, and it is known to catalyze the metabolic activation of several procarcinogens like nitrosamines, clinically used drugs and nicotine (Topcu et al., 2002). Besides liver, CYP2A6 expression was also reported in human nasal and bronchial mucosa, trachea and lung (Su et al., 1996; Ding and Kaminsky, 2003).

Taken together, our results agree with the reports of previous literature in terms of CYP3A5 and CYP4B1 detection but differ from these reports on detecting CYP2A6 mRNAs. To our knowledge, this is the first study reporting the presence of CYP2A6 in prostate tissue. However, the expressions of individual CYPs, we and others reported, need further analyses in an extended research to understand the contribution of human extrahepatic tissues to drug clearance and relative importance in chemical toxicity of hepatic clearance versus extrahepatic target tissue metabolic activities. The clinical significance of CYPs in the risk of developing PC is in the focus of our future work.
784 S. Zencir et al. · CYP Expression in Prostate